Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Recent Advances in the Therapeutic Armamentarium of Acute Myeloid Leukemia: A Focus on the 63rd American Society of Hematology Annual Meeting Abstracts

Author(s): Eşref Alperen Bayraktar, Selin Küçükyurt and Ahmet Emre Eşkazan*

Volume 28, Issue 33, 2022

Published on: 23 September, 2022

Page: [2687 - 2689] Pages: 3

DOI: 10.2174/1381612828666220912092158

Next »
[1]
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374(23): 2209-21.
[http://dx.doi.org/10.1056/NEJMoa1516192] [PMID: 27276561]
[2]
Kucukyurt S, Eskazan AE. New drugs approved for acute myeloid leukaemia in 2018. Br J Clin Pharmacol 2019; 85(12): 2689-93.
[http://dx.doi.org/10.1111/bcp.14105] [PMID: 31469910]
[3]
Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol 2022; 196(2): 316-28.
[http://dx.doi.org/10.1111/bjh.17746] [PMID: 34350585]
[4]
Nuhoğlu Kantarcı E, Eşkazan AE. Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions. Leuk Res 2022; 114: 106808.
[http://dx.doi.org/10.1016/j.leukres.2022.106808] [PMID: 35176548]
[5]
Highlights of prescribing information 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf (Accessed on: May 1, 2022).
[6]
Montesinos P, Recher C, Vives S, et al. Agile: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Blood 2021; 138 (Suppl. 1): 697.
[http://dx.doi.org/10.1182/blood-2021-147805]
[7]
Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1 -mutated acute myeloid leukemia. N Engl J Med 2022; 386(16): 1519-31.
[http://dx.doi.org/10.1056/NEJMoa2117344] [PMID: 35443108]
[8]
DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019; 133(1): 7-17.
[http://dx.doi.org/10.1182/blood-2018-08-868752] [PMID: 30361262]
[9]
Jaiswal S, Jamieson CHM, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138(2): 271-85.
[http://dx.doi.org/10.1016/j.cell.2009.05.046] [PMID: 19632178]
[10]
Daver N, Konopleva M, Maiti A, et al. Phase I/II Study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Blood 2021; 138 (Suppl. 1): 371.
[http://dx.doi.org/10.1182/blood-2021-153638]
[11]
Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018; 36(26): 2684-92.
[http://dx.doi.org/10.1200/JCO.2017.77.6112] [PMID: 30024784]
[12]
Highlights of prescribing information 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf (Accessed on: May 1, 2022).
[13]
Matthews A, Perl AE, Luger SM, et al. Real world survival outcomes of CPX-351 versus venetoclax and azacitadine for initial therapy in adult acute myeloid leukemia. Blood 2021; 138 (Suppl. 1): 795.
[http://dx.doi.org/10.1182/blood-2021-149158]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy